Thanks Ray. Recent news driving it:
BIPH: Beacon Equity Resrch Rpt ...
Biophan Technologies Research Note On Boston Scientific Research Issued By In
estrend Research Affiliate Beacon Equity Research Analyst
(financialwire.net via COMTEX) -- August 4, 2005 (FinancialWire) (Investrend
Research Syndicate) A new research note on Biophan Technologies (OTCBB: BIPH)
has been issued by Beacon Equity Research Senior Analyst, Shailesh Dhuri
regarding the closing of an equity agreement with Boston Scientific Corp. (NYSE:
BSX).
excerpt:"Boston Scientific is currently trying to gain
market share from Johnson & Johnson (NYSE: JNJ) and Guidant Corp. (NYSE: GDT) in the lucrative stent market. Boston likely has plans to use Biophan's technology to open a new market niche."
The full report is available at beaconequityresearch.com and
investrendresearch.com
In the report, Mr. Dhuri writes, "Biophan entered into a comprehensive agreement
on June 30th of this year with leading biomedical manufacturer, Boston
Scientific Corporation. The agreement called for an equity investment in Biophan
by Boston Scientific and a payment for technology licenses. The equity
transaction consists of Boston Scientific purchasing Biophan common stock
totaling $5 million, priced at a 10% premium over the average of the closing
price for the 30 calendar-day period prior to the closing (which should be over
$3.00 per share at current prices).
"The technology license includes an upfront payment of $750,000 and annual
maintenance fees, in addition to royalties and milestone payments to Biophan.
The license agreement covers multiple patents related to Magnetic Resonance
Imaging (MRI) safety and image compatibility, and includes both exclusive and
non-exclusive product categories. Boston Scientific is currently trying to gain
market share from Johnson & Johnson (NYSE: JNJ) and Guidant Corp. (NYSE: GDT) in
the lucrative stent market. Boston likely has plans to use Biophan's technology
to open a new market niche."
Beacon Equity Research, LLC is a fee-based, comprehensive investment research
firm, focusing primarily on the underserved small-cap sector. All Beacon
analysts are seasoned industry professionals and adhere to the CFA Institute's
(CFAI) stringent ethics and standards of practice guidelines. Beacon Research
does not have any investment banking relationships with any of the companies
covered. All analysts are compensated prior to performing their investment
research and are not compensated in any way based on the future performance of
the equities they follow.
Both Beacon Equity Research and Investrend subscribe to the "Standards for
Independent Research Providers" at firstresearchconsortium.com .
Beacon Research has been compensated a total of $18,000 by Biophan Technologies
for a one-year enrolment in its research program.
Complete information is available at the company's InvestorPower page at
investrend.com . Investors are
advised to read disclosures carefully before trading in the equities of any
enrolled company.
Anyone interested in receiving alerts regarding Biophan Technologies research
should email contact@investrend.com with "BIPH" in the subject line.
For up-to-the-minute news, features and links click on
financialwire.net
FinancialWire is an independent, proprietary news service of Investrend
Information, a division of Investrend Communications, Inc. It is not a press
release service and receives no compensation for its news or opinions. Other
divisions of Investrend, however, provide shareholder empowerment platforms such
as forums, independent research and webcasting. For more information or to
receive the FirstAlert daily summary of news, commentary, research reports,
webcasts, events and conference calls, click on
investrend.com
The FinancialWire NewsFeed is now available in multiple formats to your site or
desktop, free. Click on: investrend.com
URL: financialwire.net
(C) 2005 financialwire.net, Inc. All rights reserved. |
